Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\PARP.php on line 2
PARP
LE WE PMID CA
PARP6193PARP

ALK Anaplastic lymphoma kinase

Antineoplastic agents (Novel target ideas)

Apoptosis

Brain injury

BSI201 ttPARP1

Crizotinib ttALK

Diabetes mellitus (BASKET)

DNA (Repair and Toxicology)

DNMT1

Endothelial dysfunction

Epilepsy (Excitotoxicity)

Genetics (Insulator)

H2AX

Heart failure (BASKET)

Histone

JNJ26854165 ttMDM2

Mammary gland (Neoplasia)

MDM2

Mitochondria (BASKET)

Neuroprotective agents

Nitric oxide NO

Nitrosative stress

Olaparib ttPARP

PADPR

PARG

PARP

Peroxynitrite

Redox (BASKET)

RO5045337 ttMDM2

2010  
1
PARP and PARG inhibitors--new therapeutic targets in cancer treatment.
[20383759] Pathol Oncol Res 16(4): 469-78 (2010)
2008  
2
Mitochondria, oxidative stress and PARP-1 network: a new target for neuroprotective effects of tetracyclines?
[18372301] J Physiol 586(10): 2427-8 (2008)
2009  
3
Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.
[19371326] Br J Pharmacol 157(5): 695-704 (2009)
2010  
4
Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
[20725763] Cell Mol Life Sci 67(21): 3649-62 (2010)
2008  
5
Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation.
[18450439] Curr Opin Cell Biol 20(3): 294-302 (2008)
2009  
6
Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns.
[19001527] FASEB J 23(3): 672-8 (2009)
2010  
7
The roles of PARP1 in gene control and cell differentiation.
[20591646] Curr Opin Genet Dev 20(5): 512-8 (2010)
2010  
8
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
[20823146] Clin Cancer Res 16(18): 4532-42 (2010)
2010  
9
Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.
[20823142] Clin Cancer Res 16(18): 4517-26 (2010)
2010  
10
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
[20858840] Clin Cancer Res 16(19): 4702-10 (2010)
2005  
11
Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme.
[16356120] Antioxid Redox Signal 7(11-12): 1568-80 (2005)
2010  
12
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
[20373860] Future Oncol 6(4): 485-6 (2010)
2005  
13
Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal.
[16140981] Genes Dev 19(17): 1951-67 (2005)
2011  
14
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
[21424107] Mol Med 17(7-8): 854-62 (2011)
2010  
15
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.
[20459590] Breast Cancer Res 12(2): 203 (2010)
2005  
16
Nitrosative stress and pharmacological modulation of heart failure.
[15925705] Trends Pharmacol Sci 26(6): 302-10 (2005)
2011  
17
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
[21504625] J Hematol Oncol 4(-): 16 (2011)
2010  
18
PARP inhibition: PARP1 and beyond.
[20200537] Nat Rev Cancer 10(4): 293-301 (2010)
2011  
19
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
[21205831] CA Cancer J Clin 61(1): 31-49 (2011)
2011  
20
PARP inhibitors: its role in treatment of cancer.
[21718592] Chin J Cancer 30(7): 463-71 (2011)
2011  
21
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
[22084640] Ther Adv Med Oncol 3(6): 257-67 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\PARP.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\PARP.php on line 92